The effect of statin therapy on the incidence of infections: A retrospective cohort analysis

American Journal of the Medical Sciences

Volumn 347, Issue 3, 2014, Pages 211-216

  Magulick, John P ^a   Frei, Christopher R ^b,c   Ali, Sayed K ^a   Mortensen, Eric M ^d   Pugh, Mary Jo ^c   Oramasionwu, Christine U ^e   Daniels, Kelly R ^b,c   Mansi, Ishak A ^c  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Fungal; Infection; Influenza; Statin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; GENDER; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFECTION; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OUTPATIENT; RETROSPECTIVE STUDY; SCORING SYSTEM; TOBACCO USE;

ADULT; AGED; BACTERIAL INFECTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYCOSES; PNEUMONIA; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SKIN DISEASES; TEXAS; URINARY TRACT INFECTIONS;

EID: 84896738723     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31828318e2     Document Type: Article

References (65)

1. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97: 1129-35.
2. McGown CC, Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: The role of nitric oxide. Br J Anaesth 2007;98: 163-75.
3. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
4. Koh KK, Ahn JY, Jin DK, et al. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int J Cardiol 2004;97:239-44.
5. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-51.
6. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:556-62.
7. Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003;14:575-85.
8. Almog Y, Novack V, Eisinger M, et al. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007;35:372-8.
9. Chalmers JD, Singanayagam A, Murray MP, et al. Prior statin use is associated with improved outcomes in community-Acquired pneumonia. Am J Med 2008;121:1002-7.
10. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12.
11. Hackam DG, Mamdani M, Li P, et al. Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet 2006;367:413-8.
12. Kruger P, Fitzsimmons K, Cook D, et al. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006;32:75-9.
13. Liappis AP, Kan VL, Rochester CG, et al. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33:1352-7.
14. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with communityacquired pneumonia. Respir Res 2005;6:82.
15. Mortensen EM, Restrepo MI, Copeland LA, et al. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007;27:1619-26.
16. Schlienger RG, Fedson DS, Jick SS, et al. Statins and the risk of pneumonia: A population-based, nested case-control study. Pharmacotherapy 2007;27:325-32.
17. van den Hoek HL, BosWJ, de Boer A, et al. Statins and prevention of infections: Systematic review and meta-Analysis of data from large randomised placebo controlled trials. BMJ 2011;343:d7281.
18. Kruger PS, Harward ML, Jones MA, et al. Continuation of statin therapy in patients with presumed infection: A randomized controlled trial. Am J Respir Crit Care Med 2011;183:774-81.
19. Leung S, Pokharel R, Gong MN. Statins and outcomes in patients with bloodstream infection: A propensity-matched analysis. Crit Care Med 2012;40:1064-71.
20. Majumdar SR, McAlister FA, Eurich DT, et al. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population based prospective cohort study. BMJ 2006;333:999.
21. Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: A population-based cohort study. Crit Care Med 2006;34:1080-6.
22. Yang KC, Chien JY, Tseng WK, et al. Statins do not improve shortterm survival in an oriental population with sepsis. Am J Emerg Med 2007;25:494-501.
23. Fernandez R, De Pedro VJ, Artigas A. Statin therapy prior to ICU admission: Protection against infection or a severity marker? Intensive Care Med 2006;32:160-4.
24. Falagas ME, Makris GC, Matthaiou DK, et al. Statins for infection and sepsis: A systematic review of the clinical evidence. J Antimicrob Chemother 2008;61:774-85.
25. Janda S, Young A, Fitzgerald JM, et al. The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-Analysis. J Crit Care 2010;25:656.e7-22.
26. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: A systematic review and meta-Analysis. Arch Intern Med 2009;169:1658-67.
27. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: A cautionary tale. Circulation 2009;119:2051-7.
28. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipidlowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54.
29. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33.
30. Kugler J. Military Health System Patient Centered Medical Home Guide. Office of the Chief Medical Officer, Tricare. Department of Defense. June 2011. Available at: Http://www.tricare.mil/tma/ocmo/ download/MHSPCMHGuide.pdf. Accessed January 11, 2012.
31. Elmitwalli T, Otterpohl R. Grey water treatment in upflow anaerobic sludge blanket (UASB) reactor at different temperatures. Water Sci Technol 2011;64:610-7.
32. George SZ, Childs JD, Teyhen DS, et al. Brief psychosocial education, not core stabilization, reduced incidence of low back pain: Results from the Prevention of Low Back Pain in the Military (POLM) cluster randomized trial. BMC Med 2011;9:128.
33. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
34. Elixhauser A, Steiner C, Palmer L. Clinical Classifications Software (CCS) for ICD-9-CM. In: Databases and Related Tools From the Healthcare Cost and Utilization Project (HCUP). U.S. Agency for Healthcare Research and Quality; 2012: Appendix A. Available at http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ ccs.jsp. Accessed on January 11, 2012.
35. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
36. Selim AJ, Fincke G, Ren XS, et al. Comorbidity assessments based on patient report: Results from the Veterans Health Study. J Ambul Care Manage 2004;27:281-95.
37. Schindeler SK, Muscatello DJ, Ferson MJ, et al. Evaluation of alternative respiratory syndromes for specific syndromic surveillance of influenza and respiratory syncytial virus: A time series analysis. BMC Infect Dis 2009;9:190.
38. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: A cohort study. Clin Infect Dis 2011;53:413-21.
39. Chang JS, Tsai CR, Tsai YW, et al. Medically diagnosed infections and risk of childhood leukaemia: A population-based case-control study. Int J Epidemiol 2012;41:1050-9.
40. Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-Associated pneumonia. Eur Respir J 2011;38:878-87.
41. Frei CR, Mortensen EM, Copeland LA, et al. Disparities of care for African-Americans and Caucasians with community-Acquired pneumonia: A retrospective cohort study. BMC Health Serv Res 2010;10:143.
42. Turpin RS, Canada T, Rosenthal V, et al. Bloodstream infections associated with parenteral nutrition preparation methods in the United States: A retrospective, large database analysis. JPEN J Parenter Enteral Nutr 2012;36:169-76.
43. Shah SS, Ratner AJ. Trends in invasive pneumococcal disease-Associated hospitalizations. Clin Infect Dis 2006;42:e1-5.
44. Carl DE, Grossman C, Behnke M, et al. Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure. Hemodial Int 2010;14:11-7.
45. Frei CR, Makos BR, Daniels KR, et al. Emergence of communityacquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. J Pediatr Surg 2010;45:1967-74.
46. Fleming DM, Elliot AJ, Kendall H. Skin infections and antibiotic prescribing: A comparison of surveillance and prescribing data. Br J Gen Pract 2007;57:569-73.
47. Iribarren C, Jacobs DR Jr, Sidney S, et al. Cohort study of serum total cholesterol and in-hospital incidence of infectious diseases. Epidemiol Infect 1998;121:335-47.
48. Clark DO, Von Korff M, Saunders K, et al. A chronic disease score with empirically derived weights. Med Care 1995;33:783-95.
49. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55:1466-73.
50. Coleman CI, Lucek DM, Hammond J, et al. Preoperative statins and infectious complications following cardiac surgery. Curr Med Res Opin 2007;23:1783-90.
51. Dublin S, Jackson ML, Nelson JC, et al. Statin use and risk of community acquired pneumonia in older people: Population based case-control study. BMJ 2009;338:b2137.
52. Myles PR, Hubbard RB, McKeever TM, et al. Risk of communityacquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: A population-based case-control study. Pharmacoepidemiol Drug Saf 2009;18:269-75.
53. van de Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61: 957-61.
54. Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range of health outcomes: A cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009;67:99-109.
55. van den Hoek HL, BosWJ, de Boer A, et al. Statins and prevention of infections: Systematic review and meta-Analysis of data from large randomised placebo controlled trials. BMJ 2011;343:d7281.
56. Donnino MW, Cocchi MN, Howell M, et al. Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med 2009;16:230-4.
57. Gupta R, Plantinga LC, Fink NE, et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA 2007;297: 1455-64.
58. Forrest GN, Kopack AM, Perencevich EN. Statins in candidemia: Clinical outcomes from a matched cohort study. BMC Infect Dis 2010;10:152.
59. Spanakis EK, Kourkoumpetis TK, Livanis G, et al. Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. Mayo Clin Proc 2010;85:1073-9.
60. Thompson JN, Huycke MM, Greenfield RA, et al. Case-control study of statin prevention of mould infections. Mycoses 2011;54:e481-5.
61. Brett SJ, Myles P, Lim WS, et al. Pre-Admission statin use and in-hospital severity of 2009 pandemic influenza A (H1N1) disease. PLoS One 2011;6:e18120.
62. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: A multistate study. J Infect Dis 2012;205:13-9.
63. Mortensen EM, Restrepo MI, Copeland LA, et al. Statins and outcomes in patients with pneumonia: Not only healthy user bias. BMJ 2006;333:1123-4.
64. Pines JM. Measuring antibiotic timing for pneumonia in the emergency department: Another nail in the coffin. Ann Emerg Med 2007;49:561-3.
65. Kanwar M, Brar N, Khatib R, et al. Misdiagnosis of communityacquired pneumonia and inappropriate utilization of antibiotics: Side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-9.